This site uses cookies, including third-party cookies, that help us to provide and improve our services.

Privacy Policy
- Global Locations -
Headquarters
Future Market Insights, Inc.
Christiana Corporate, 200 Continental Drive, Suite 401, Newark, Delaware - 19713, United States
T: +1-845-579-5705
MEA
Market Access DMCC
1602-6 Jumeirah Bay X2 Tower, Plot No: JLT-PH2-X2A,
Jumeirah Lakes Towers, Dubai,
United Arab Emirates
Americas
Future Market Insights
616 Corporate Way, Suite 2-9018,
Valley Cottage, NY 10989,
United States
T: +1-347-918-3531
Europe
Future Market Insights
3rd Floor, 207 Regent Street,
London W1B 3HH
United Kingdom
T: + 44 (0) 20 8123 9659
D: +44 (0) 20 3287 4268
APAC
Future Market Insights
Office No. 401-A, 4th Floor,
VANTAGE 9, S.No. 36/1/1,
Baner, Pune 411045 India

Generic Oncology Drugs Market

Market Insights on Generic Oncology Drugs covering sales outlook, demand forecast & up-to-date key trends

Generic Oncology Drugs Market by Molecule Type, Route of Administration, Distribution Channel& Region - Forecast 2022 – 2028

Generic Oncology Drugs Market Outlook (2022-2028)

[200 Pages Report] The global generic oncology drugs market size reached a valuation of US$ 24.5 Bn in 2022 and is expected to grow at a robust CAGR of 6.0% between 2022 and 2028, totaling over US$ 34.8 Bn by the end of 2028.

Rising sales of generic oncology drugs is attributable to the increasing prevalence of various cancer types and growing demand for low-cost cancer therapeutics especially across developing and underdeveloped regions.

Generic Oncology Drugs Market Size (2022)

US$ 24.5 Bn

Generic Oncology Drugs Market Size (2028)

US$ 34.8 Bn

Global Market Growth Rate (2022-2028)

6% CAGR

Market Share of Large Molecules

53.1%

A generic drug is a medication that contains the same chemical substance as a drug that was originally protected by chemical patents. It provides the same therapeutic effect as that of the original drug and is allowed for sale after the patents on the original drug expire.

The dramatic rise in cancer drug prices presents a tough challenge to treatment access and cancer outcomes. A large portion of the world population suffering from cancer is unable to afford proper cancer treatment due to staggering cancer treatment prices. As a result, they are continuously looking for low-cost cancer therapeutics. This has brought generic oncology drugs market into the spotlight.

Introduction of generic drugs in oncology has provided a new ray of hope to millions of patients suffering from various types of cancers, who cannot afford high-cost treatments. They have become ideal cost-effective alternatives to branded medicines and are being increasingly consumed by cancer patients worldwide.

Rise in cases of cancer coupled with growing awareness about the benefits of generic oncology drugs such as their cost effectiveness, is expected to provide a strong thrust to the growth of generic oncology drugs market during the forecast period.

Similarly, growing demand for specialty generics and increasing government initiatives and investments will create opportunities for generic oncology drugs manufacturers in future.

Currently, consumption of generic oncology drugs accounts for 17% share of the global oncology drugs market.

Customize this Report

Let us know your requirement to get
100% FREE customization

How The Market Progressed Till June 2022?

Particulars

Details

H1, 2021

6.17%

H1, 2022 Projected

6.04%

H1, 2022 Outlook

5.14%

BPS Change - H1, 2022 (O) – H1, 2022 (P)

(-) 90 ↓

BPS Change – H1, 2022 (O) – H1, 2021

(-) 103 ↓

According to Future Market Insights' analysis, the global generic oncology drugs market expects to drop by 103 Basis Point Share (BPS) in H1-2022 as compared to H1- 2021. Whereas in comparison to H1-2022 Projected value, the market during H1-2022 outlook period will show a dip of 90 BPS.

The resultant decline in the BPS values is associated with the existing international variability in the safety of generic oncology drugs, thus posing regulatory along with patient safety concerns. Moreover, drawbacks in generic pharmaceuticals production in developing countries such as India, due to a less intensive regulatory oversight has further deteriorated the BPS value change.

The market will however observe a positive growth outlook, owed to the significantly improved cost-effectiveness and cost–utility offered by the generic versions of costly oncology drugs in the developed countries.

The market is subject to changes as per the clinical, policy, regulatory and patient safety factors, in accordance to the macroeconomic and industry standards. The key development in the market includes the launch of the cancer drug Ibrance, for targeted therapy.

Demand Analysis Of Generic Oncology Drugs (2013 To 2021) Vs Industry Outlook (2022 To 2028)

The global demand for generic oncology drugs is set to grow at a healthy CAGR of 6.0% between 2022 and 2028, in comparison to 5.8% CAGR registered from 2014 to 2021. Growth in the generic oncology drugs market is driven by rising incidence of cancer, growing awareness among people about cancer and its treatments, cost effective nature of generic oncology drugs, favorable government support, and rise in new generic oncology drug launches and approvals.

With skyrocketing costs of cancer therapeutics and rising need for quality medical options, the interest in generics oncology drugs has increased all over the world. Generic oncology drugs are a chemical copy of original band, with the same active ingredients.

These drugs tend to cost less than their brand-name counterparts because generic drug applicants do not have to repeat the costly clinical trials. Generic drugs in oncology have become essential because some anticancer drugs are only available as generics.

Increasing incidence of cancer is a major factor boosting the growth of generic oncology drugs market and the trend is likely to continue during the forecast period. According to the World Health Organization (WHO), with around 10 million deaths in 2020, cancer was the leading cause of death worldwide.

In order to reduce this mortality rate, people opt for various cancer treatments including generic oncology drugs. This surge in numerous types of cancers such as breast cancer and lung cancer will continue to boost the sale of generic oncology drugs like breast cancer drugs and lung cancer therapeutics, thereby improving the generic oncology drugs market share.

Similarly, growing popularity of generic oncology drugs due to their cost-effective nature along with growing popularity of super generics is expected to boost the generic oncology drugs market growth during the forecast period. Generic oncology drugs are usually priced at affordable rates with costs that are up to 80% less than branded drugs. As a result, people are showing a keen inclination towards using these generic oncology drugs.

Leading generic oncology drugs manufacturers are frequently launching new products in order to meet the rising demand. This will ignite the growth of generic oncology medicines market during the forecast period.

Generic Oncology Drugs Market Download Report Brochure

Which Factors Are Restraining The Growth Of Generic Oncology Drugs Market?

“Oncologists’ Scepticism on Effectiveness Could Hinder Generic Oncology Drug Sales”

Despite its optimistic stance, the global generic oncology drugs market is facing various challenges that are restraining its growth to some extent. Some of these factors include scepticism about the effectiveness of generic oncology drugs, longer approvals time, and increasing usage of alternative cancer treatments.

Sabyasachi Ghosh
Principal Consultant
LinkedIn
Talk to Analyst

Find your sweet spots for generating winning opportunities in this market.

Talk to Analyst

Country-Wise Analysis

What is the Demand Outlook for the India Generic Oncology Drugs Market?

“Rapid Rise in the Export of Generic Medicines and Growing Demand for Affordable Cancer Treatments Propelling Sales of Generic Oncology Drugs in India”

As per FMI, the generic oncology drugs market in India is expected to grow at a healthy pace during the forecast period, owing to the rapid surge in cancer cases, rising adoption of cancer diagnostic technologies like oncology blood testing, growing health awareness, rise in export of medicines, and increasing demand for low-cost medicines.

Over the years, India has become one of the biggest exporters of generic medicines to several developed countries including the U.S., Russia, and the U.K. Africa. According to the India Brand Equity Foundation (IBEF), the country (India) exported pharma products worth US$ 24.62 billion during 2021 –2022.

Factors such as easy availability of labors, low cost of manufacturing, and supportive government initiatives are attracting generic oncology drug manufacturers to establish their bases in India. This will bode well for the India Generic oncology drugs market during the forecast period.

Indian based pharmaceutical giants like Dr. Reedy's Laboratories and Aurobindo Pharma, are playing a key role in expanding the generic oncology drugs market size in the country. These generic oncology drugs manufacturers are developing novel generic drugs to penetrate attractive markets. For instance, in October 2021, DR Reddy's Laboratories launched its anti-cancer drug, Abiraterone Acetate in Chinese market.

How Will Growth Unfold in the U.S. Generic Oncology Drugs Market?

“Rising Incidence of Cancer and Increase in Generic Drug Launches and Approvals Spurring Growth of Generic Oncology Drugs Market in the U.S.”

The U.S. currently leads the North American generic oncology drugs market and is expected to grow at a considerable pace during the forecast period between 2022 and 2032.

Growth in the U.S. generic oncology drugs market is driven by rapid surge in cancer cases, growing adoption of branded generics, increasing healthcare expenditure, high cancer diagnostic screening, availability of various innovative cancer treatments, and large presence of leading generic drug manufacturers.

In recent years instances of multiple cancers have increased substantially in the U.S. and this trend is anticipated to continue even during the forecast period. According to the American Cancer Society (ACS), there will be an estimated 1.9 million new cancer cases and 609,360 cancer deaths in the United States during 2022. Driven by this, demand for generic oncology drugs is expected to rise at a robust pace during the forecast period.

Similarly, increasing investments in research and development, rapid growth of cancer supportive care products market, and rise in new drug development and approvals will improve the generic oncology drugs market share in the country during the forthcoming years.

Category-Wise Analysis

Which Molecule Type Segment Will Contribute Most to the Generic Oncology Drugs Market?

“Demand for Small Molecule Generic Oncology Drugs to Grow at an Exponential Pace”

Based on molecule type, the global generic oncology drugs market is segmented into large molecule generic oncology drugs and small molecule generic oncology drugs. Among these two, large molecule generic oncology drugs segment currently holds the largest share of 53.1% of the global generic oncology drugs market.

However, with growing consumer preference for small molecule drugs due to their various benefits, growing popularity of personalized drug development, and increasing research and development activities, the small molecule generic oncology drugs segment is expected to grow at a relatively higher CAGR during the forecast period.

Small molecule generic oncology drugs are gradually gaining popularity on account of their enhanced safety, minimal side effects, and high drug efficacy. Their molecular size and complexity enable them to reach target sites easily.

Similarly, expansion of small-molecule injectable market will further support the growth of this segment during the forecast period.

Which Distribution Channel Dominates the Global generic oncology drugs market?

“Online Pharmacies to Remain the Mostly Preferred Distribution Channel for Generic Oncology Drugs”

Emerging generic oncology market trends indicate that the online pharmacies segment is likely to grow at the highest CAGR during the forecast period. This can be attributed to rising consumer inclination towards purchasing generic oncology drugs from their homes to save money and time and rise in the number of online pharmacies worldwide. Further, online pharmacies also render higher interoperability in comparison to the hospital systems.

Become a MarketNgage Insider

An unified Market Research Subscription Platform, built for today’s disparate research needs.

Who Are The Top Players In Generic Oncology Drugs Market?

Some of the leading players in generic oncology drugs market include Novartis AG, CELGENE CORPORATION, Merck & Company Inc., Pfizer Inc., GlaxoSmithKline plc, Teva Pharmaceutical Industries Ltd., NATCO Pharma Limited, Aurobindo Pharma, Hikma Pharmaceuticals PLC, and Mylan N.V. They are committed to discovering, investigating, and developing transformative therapies that improve the outlook for cancer patients worldwide.

These leading generic oncology drugs manufacturers are increasingly investing in research and development for introducing novel oncology drugs with better effectiveness and low costs.

Besides this, they have adopted strategies like new product launches and approvals, partnerships, collaborations, acquisitions, mergers, and strengthening of distribution channels to gain a competitive edge in the global generic oncology drugs market.

For instance,

  • In February 2021, Glenmark Pharmaceuticals, a research-led, global integrated pharmaceutical company, launched SUTIB, the generic version of Sunitinib oral capsules to treat kidney cancer in India. The new generic drug is priced 96% lower than the innovator brand to make it affordable to maximum patients.
  • In February 2022, Sandoz, a pharmaceutical company headquartered in Switzerland, launched generic oncology medicine lenalidomide in 19 countries across Europe to provide patients access to affordable, high-quality medicines.
  • In June 2022, NATCO Pharma Limited announced the launch of the first generic version of Nexavar (Sorafenib) tablets in the U.S. market.

Key Segments Of Generic Oncology Drugs Industry Survey

Generic Oncology Drugs Market by Molecule Type:

  • Large Molecule Generic Oncology Drugs
  • Small Molecule Generic Oncology Drugs

Generic Oncology Drugs Market by Route of Administration:

  • Oral Generic Oncology Drugs
  • Parenteral Generic Oncology Drugs

Generic Oncology Drugs Market by Distribution Channel:

  • Generic Oncology Drugs Sold at Hospital Pharmacies
  • Generic Oncology Drugs Sold at Retail Pharmacies
  • Generic Oncology Drugs Sold at Online Pharmacies
  • Generic Oncology Drugs Sold at Managed Care Institutions

Generic Oncology Drugs Market by Region:

  • North America Generic Oncology Drugs Market
  • Latin America Generic Oncology Drugs Market
  • Europe Generic Oncology Drugs Market
  • East Asia Generic Oncology Drugs Market
  • South Asia & Pacific Generic Oncology Drugs Market
  • Middle East & Africa (MEA) Generic Oncology Drugs Market

Generic Oncology Drugs Market Scope

With the aim of providing a detailed analysis of the global generic oncology drugs market, Future Market Insights latest report delves deep into various market governing factors such as growth drivers, restraints, consumer demands, emerging generic oncology drugs market trends. It offers insights into leading regional pockets and market segments.

The report also provides in-depth analysis regarding the competitive landscape of generic oncology drugs market and explains how key generic oncology drugs manufacturers are innovating to meet consumer demands.

Besides this, FMI also examines the impact of rising cancer cases and advancing cancer diagnostic technologies on the overall sales of generic oncology drugs. The report further highlights factors pushing demand for generic oncology drugs across developing regions like India and China.

The Generic Oncology Drugs Market Analysis Includes:

  • A 6-year realistic sales forecast of generic oncology drugs across multiple end use verticals
  • Key market dynamics including drivers, restraints, and emerging opportunities
  • Generic oncology drugs market segmentation and information about leading segments
  • Insights into latest generic oncology drugs market trends
  • Details of leading generic oncology drugs manufacturers and their respective growth strategies to penetrate attractive markets
  • Opportunity assessment
  • The winning imperatives in generic oncology drugs market
  • Supply chain analysis
  • Pricing analysis

Attribute

Details

Projected Market Size (2028)

US$ 34.8 Bn

Estimated Growth Rate (2022-2028)

6%

Forecast Period

2022-2028

Historic Data Available for

2013-2021

Market Analysis

USD Million for Value

Report Coverage

Market forecast, company share analysis, competition intelligence, DROT analysis, market dynamics and challenges, and strategic growth initiatives

Key Segments Covered

  • Molecule Type
  • Route of Administration
  • Distribution Channel
  • Region

Key regions covered

North America

  • US
  • Canada
  • Rest of North America

Latin America

  • Brazil
  • Argentina
  • Mexico
  • Rest of Latin America

Western Europe

  • Germany
  • U.K.
  • France
  • Rest of Western Europe

Eastern Europe

  • Russia
  • Spain
  • Rest of Eastern Europe

South Asia Pacific

  • China
  • India
  • Japan
  • Malaysia
  • Thailand
  • Indonesia
  • South Korea
  • Rest of South Asia & Pacific

Middle East & Africa

  • GCC Countries
  • Turkey
  • Israel
  • Rest of MEA

Rest of the World

  • Oceania
  • Africa
  • South America

Distribution Channel

  • Hospital Pharmacies
  • Retail Pharmacies
  • Online Pharmacies
  • Managed Care Institutions

Key companies profiled

Novartis AG, CELGENE CORPORATION, Merck & Company Inc., Pfizer Inc., GlaxoSmithKline plc, Teva Pharmaceutical Industries Ltd., NATCO Pharma Limited, Aurobindo Pharma, Hikma Pharmaceuticals PLC, and Mylan N.V.

Customization & pricing

Available upon request

Frequently Asked Questions

The global generic oncology drugs market reached a valuation of US$ 24.5 Bn in 2022.

Demand for generic oncology drugs is expected to rise at 6% CAGR during the forecast period, totaling US$ 34.8 Bn by 2028.

Currently, large molecule generic oncology drugs segment leads the market with around 53.1% share.

Increasing prevalence of cancer, growing awareness about cancer and its various treatments, and continuous new product launches are some of the key factors shaping the growth of generic oncology drugs market.

Novartis AG, GlaxoSmithKline plc, CELGENE CORPORATION, Pfizer Inc., Teva Pharmaceutical Industries Ltd., Aurobindo Pharma, and Merck & Company Inc. are some of the prominent players operating in generic oncology drugs market.

Table of Content

1. Executive Summary

     1.1. Market Overview

     1.2. Market Analysis

     1.3. FMI Analysis and Recommendations

     1.4. Wheel of Fortune

2. Market Introduction

     2.1. Market Taxonomy

     2.2. Market Definition

3. Generic Oncology Drugs Market Opportunity Analysis 

     3.1. Macro-Economic Factors

     3.2. Opportunity Analysis

4. Market Background

     4.1. PESTLE Analysis

     4.2. Market Dynamics

            4.2.1. Drivers

            4.2.2. Restraints

            4.2.3. Trends

     4.3. Regulatory Scenario

5. Key Inclusions

     5.1. Generic Oncology Drugs Pipeline

6. North America Generic Oncology Drugs Market Analysis 2013–2021 and Forecast 2022–2028

     6.1. Introduction

     6.2. Historical Market Size (US$ Mn) Analysis By Country, 2013-2021

            6.2.1. U.S.

            6.2.2. Canada

     6.3. Market Size (US$ Mn) Forecast By Country, 2022-2028

     6.4. Historical Market Size (US$ Mn) Trend Analysis By Molecule Type, 2013-2021

            6.4.1. Large Molecule

            6.4.2. Small Molecule

     6.5. Market Size (US$ Mn) Forecast By Molecule Type, 2022-2028

     6.6. Historical Market Size (US$ Mn) Trend Analysis By Route of Administration, 2013-2021

            6.6.1. Oral

            6.6.2. Parenteral

     6.7. Market Size (US$ Mn) Forecast By Route of Administration, 2022-2028

     6.8. Historical Market Size (US$ Mn) Trend Analysis By Distribution Channel, 2013-2021

            6.8.1. Hospital Pharmacy

            6.8.2. Retail Pharmacy

            6.8.3. Online Pharmacy

            6.8.4. Managed Care Institutions

     6.9. Market Size (US$ Mn) Forecast By Distribution Channel, 2022-2028

     6.10. Drivers and Restraints: Impact Analysis

     6.11. Market Attractiveness Analysis

            6.11.1. By Country

            6.11.2. By Molecule Type

            6.11.3. By Route of Administration

            6.11.4. By Distribution Channel

7. Western Europe Generic Oncology Drugs Market Analysis 2013–2021 and Forecast 2022–2028

     7.1. Introduction

     7.2. Historical Market Size (US$ Mn) Analysis By Country, 2013-2021

            7.2.1. Germany

            7.2.2. U.K

            7.2.3. France

            7.2.4. Italy

            7.2.5. Spain

            7.2.6. Rest of Western Europe

     7.3. Market Size (US$ Mn) Forecast By Country, 2022-2028

     7.4. Historical Market Size (US$ Mn) Trend Analysis By Molecule Type, 2013-2021

            7.4.1. Large Molecule

            7.4.2. Small Molecule

     7.5. Market Size (US$ Mn) Forecast By Molecule Type, 2022-2028

     7.6. Historical Market Size (US$ Mn) Trend Analysis By Route of Administration, 2013-2021

            7.6.1. Oral

            7.6.2. Parenteral

     7.7. Market Size (US$ Mn) Forecast By Route of Administration, 2022-2028

     7.8. Historical Market Size (US$ Mn) Trend Analysis By Distribution Channel, 2013-2021

            7.8.1. Hospital Pharmacy

            7.8.2. Retail Pharmacy

            7.8.3. Online Pharmacy

            7.8.4. Managed Care Institutions

     7.9. Market Size (US$ Mn) Forecast By Distribution Channel, 2022-2028

     7.10. Drivers and Restraints: Impact Analysis

     7.11. Market Attractiveness Analysis

            7.11.1. By Country

            7.11.2. By Molecule Type

            7.11.3. By Route of Administration

            7.11.4. By Distribution Channel

8. Eastern Europe Generic Oncology Drugs Market Analysis 2013–2021 and Forecast 2022–2028

     8.1. Introduction

     8.2. Historical Market Size (US$ Mn) Analysis By Country, 2013-2021

            8.2.1. Russia

            8.2.2. Poland

            8.2.3. Rest of Eastern Europe

     8.3. Market Size (US$ Mn) Forecast By Country, 2022-2028

     8.4. Historical Market Size (US$ Mn) Trend Analysis By Molecule Type, 2013-2021

            8.4.1. Large Molecule

            8.4.2. Small Molecule

     8.5. Market Size (US$ Mn) Forecast By Molecule Type, 2022-2028

     8.6. Historical Market Size (US$ Mn) Trend Analysis By Route of Administration, 2013-2021

            8.6.1. Oral

            8.6.2. Parenteral

     8.7. Market Size (US$ Mn) Forecast By Route of Administration, 2022-2028

     8.8. Historical Market Size (US$ Mn) Trend Analysis By Distribution Channel, 2013-2021

            8.8.1. Hospital Pharmacy

            8.8.2. Retail Pharmacy

            8.8.3. Online Pharmacy

            8.8.4. Managed Care Institutions

     8.9. Market Size (US$ Mn) Forecast By Distribution Channel, 2022-2028

     8.10. Drivers and Restraints: Impact Analysis

     8.11. Market Attractiveness Analysis

            8.11.1. By Country

            8.11.2. By Molecule Type

            8.11.3. By Route of Administration

            8.11.4. By Distribution Channel

9. Latin America Generic Oncology Drugs Market Analysis 2013–2021 and Forecast 2022–2028

     9.1. Introduction

     9.2. Historical Market Size (US$ Mn) Analysis By Country, 2013-2021

            9.2.1. Brazil

            9.2.2. Mexico

            9.2.3. Rest of Latin America

     9.3. Market Size (US$ Mn) Forecast By Country, 2022-2028

     9.4. Historical Market Size (US$ Mn) Trend Analysis By Molecule Type, 2013-2021

            9.4.1. Large Molecule

            9.4.2. Small Molecule

     9.5. Market Size (US$ Mn) Forecast By Molecule Type, 2022-2028

     9.6. Historical Market Size (US$ Mn) Trend Analysis By Route of Administration, 2013-2021

            9.6.1. Oral

            9.6.2. Parenteral

     9.7. Market Size (US$ Mn) Forecast By Route of Administration, 2022-2028

     9.8. Historical Market Size (US$ Mn) Trend Analysis By Distribution Channel, 2013-2021

            9.8.1. Hospital Pharmacy

            9.8.2. Retail Pharmacy

            9.8.3. Online Pharmacy

            9.8.4. Managed Care Institutions

     9.9. Market Size (US$ Mn) Forecast By Distribution Channel, 2022-2028

     9.10. Drivers and Restraints: Impact Analysis

     9.11. Market Attractiveness Analysis

            9.11.1. By Country

            9.11.2. By Molecule Type

            9.11.3. By Route of Administration

            9.11.4. By Distribution Channel

10. Asia Pacific Excluding China & Japan Generic Oncology Drugs Market Analysis 2013–2021 and Forecast 2022–2028

     10.1. Introduction

     10.2. Historical Market Size (US$ Mn) Analysis By Country, 2013-2021

            10.2.1. India

            10.2.2. Australia and New Zealand

            10.2.3. ASEAN

            10.2.4. Rest of APECJ

     10.3. Market Size (US$ Mn) Forecast By Country, 2022-2028

     10.4.Historical Market Size (US$ Mn) Trend Analysis By Molecule Type, 2013-2021

            10.4.1. Large Molecule

            10.4.2. Small Molecule

     10.5. Market Size (US$ Mn) Forecast By Molecule Type, 2022-2028

     10.6.Historical Market Size (US$ Mn) Trend Analysis By Route of Administration, 2013-2021

            10.6.1. Oral

            10.6.2. Parenteral

     10.7.Market Size (US$ Mn) Forecast By Route of Administration, 2022-2028

     10.8.Historical Market Size (US$ Mn) Trend Analysis By Distribution Channel, 2013-2021

            10.8.1. Hospital Pharmacy

            10.8.2. Retail Pharmacy

            10.8.3. Online Pharmacy

            10.8.4. Managed Care Institutions

     10.9.Market Size (US$ Mn) Forecast By Distribution Channel, 2022-2028

     10.10. Drivers and Restraints: Impact Analysis

     10.11. Market Attractiveness Analysis

            10.11.1. By Country

            10.11.2. By Molecule Type

            10.11.3. By Route of Administration

            10.11.4. By Distribution Channel

11. China Generic Oncology Drugs Market Analysis 2013–2021 and Forecast 2022–2028

     11.1. Introduction

     11.2.Historical Market Size (US$ Mn) Trend Analysis By Molecule Type, 2013-2021

            11.2.1. Large Molecule

            11.2.2. Small Molecule

     11.3. Market Size (US$ Mn) Forecast By Molecule Type, 2022-2028

     11.4.Historical Market Size (US$ Mn) Trend Analysis By Route of Administration, 2013-2021

            11.4.1. Oral

            11.4.2. Parenteral

     11.5.Market Size (US$ Mn) Forecast By Route of Administration, 2022-2028

     11.6.Historical Market Size (US$ Mn) Trend Analysis By Distribution Channel, 2013-2021

            11.6.1. Hospital Pharmacy

            11.6.2. Retail Pharmacy

            11.6.3. Online Pharmacy

            11.6.4. Managed Care Institutions

     11.7. Market Size (US$ Mn) Forecast By Distribution Channel, 2022-2028

     11.8. Drivers and Restraints: Impact Analysis

     11.9. Market Attractiveness Analysis

            11.9.1. By Molecule Type

            11.9.2. By Route of Administration

            11.9.3. By Distribution Channel

12. Japan Generic Oncology Drugs Market Analysis 2013–2021 and Forecast 2022–2028

     12.1. Introduction

     12.2.Historical Market Size (US$ Mn) Trend Analysis By Molecule Type, 2013-2021

            12.2.1. Large Molecule

            12.2.2. Small Molecule

     12.3. Market Size (US$ Mn) Forecast By Molecule Type, 2022-2028

     12.4.Historical Market Size (US$ Mn) Trend Analysis By Route of Administration, 2013-2021

            12.4.1. Oral

            12.4.2. Parenteral

     12.5. Market Size (US$ Mn) Forecast By Route of Administration, 2022-2028

     12.6. Historical Market Size (US$ Mn) Trend Analysis By Distribution Channel, 2013-2021

            12.6.1. Hospital Pharmacy

            12.6.2. Retail Pharmacy

            12.6.3. Online Pharmacy

            12.6.4. Managed Care Institutions

     12.7. Market Size (US$ Mn) Forecast By Distribution Channel, 2022-2028

     12.8. Drivers and Restraints: Impact Analysis

     12.9. Market Attractiveness Analysis

            12.9.1. By Molecule Type

            12.9.2. By Route of Administration

            12.9.3. By Distribution Channel

13. Middle East and Africa Generic Oncology Drugs Market Analysis 2013–2021 and Forecast 2022–2028

     13.1. Introduction

     13.2. Historical Market Size (US$ Mn) Analysis By Country, 2013-2021

            13.2.1. GCC Countries

            13.2.2. South Africa

            13.2.3. Rest of Middle East and Africa

     13.3. Market Size (US$ Mn) Forecast By Country, 2022-2028

     13.4. Historical Market Size (US$ Mn) Trend Analysis By Molecule Type, 2013-2021

            13.4.1. Large Molecule

            13.4.2. Small Molecule

     13.5. Market Size (US$ Mn) Forecast By Molecule Type, 2022-2028

     13.6.Historical Market Size (US$ Mn) Trend Analysis By Route of Administration, 2013-2021

            13.6.1. Oral

            13.6.2. Parenteral

     13.7. Market Size (US$ Mn) Forecast By Route of Administration, 2022-2028

     13.8. Historical Market Size (US$ Mn) Trend Analysis By Distribution Channel, 2013-2021

            13.8.1. Hospital Pharmacy

            13.8.2. Retail Pharmacy

            13.8.3. Online Pharmacy

            13.8.4. Managed Care Institutions

     13.9. Market Size (US$ Mn) Forecast By Distribution Channel, 2022-2028

     13.10. Drivers and Restraints: Impact Analysis

     13.11. Market Attractiveness Analysis

            13.11.1. By Country

            13.11.2. By Molecule Type

            13.11.3. By Route of Administration

            13.8.4. By Distribution Channel

14. Forecast Factors: Relevance and Impact

15. Forecast Assumptions

16. Competition Analysis

     16.1.Competition Dashboard

     16.2.Company Deep Dive

            16.2.1. Novartis AG

                      16.2.1.1. Overview

                      16.2.1.2. Treatment and Application Portfolio

                      16.2.1.3. Product Footprint

                      16.2.1.4. Sales Footprint

                      16.2.1.5. Channel Footprint

                      16.2.1.6. Strategy

                                 16.2.1.6.1.1 Marketing Strategy

                                 16.2.1.6.1.2. Treatment Strategy

                                 16.2.1.6.1.3. Channel Strategy

            16.2.2. Pfizer Inc.

            16.2.3. GlaxoSmithKline plc

            16.2.4. CELGENE CORPORATION

            16.2.5. Teva Pharmaceutical Industries Ltd.

            16.2.6. Merck & Company, Inc

            16.2.7. Aurobindo Pharma.

            16.2.8. Hikma Pharmaceuticals PLC 

            16.2.9. Mylan N.V.

            16.2.10. NATCO Pharma Limited.

17. Global Generic Oncology Drugs Market Analysis 2013–2021 and Forecast 2022–2028 By Region

     17.1. Introduction / Key Findings

     17.2. Historical Market Size (US$ Mn) Analysis By Region

            17.2.1. North America

            17.2.2. Western Europe

            17.2.3. Eastern Europe

            17.2.4. Latin America

            17.2.5. Asia Pacific Excluding Japan

            17.2.6. Japan

            17.2.7. China

            17.2.8. Middle East and Africa

     17.3. Market Size (US$ Mn) Forecast By Region

     17.4. Market Attractiveness Analysis By Region

18. Global Generic Oncology Drugs Market Analysis 2013–2021 and Forecast 2022–2028, By Molecule Type

     18.1. Introduction/Key Finding

     18.2. Historical Market Size (US$ Mn) Trend Analysis By Molecule Type, 2013-2021

            18.2.1. Large Molecule

            18.2.2. Small Molecule

     18.3.Market Size (US$ Mn) Forecast By Molecule Type, 2022-2028

     18.4. Market Attractiveness Analysis By Molecule Type

19. Global Generic Oncology Drugs Market Analysis 2013–2021 and Forecast 2022–2028, By Route Of Administration

     19.1.Introduction/Key Finding

     19.2. Historical Market Size (US$ Mn) Trend Analysis By Route Of Administration, 2013-2021

            19.2.1. Oral

            19.2.2. Parenteral

     19.3.Market Size (US$ Mn) Forecast By Route Of Administration, 2022-2028

     19.4.Market Attractiveness Analysis By Route Of Administration

20. Global Generic Oncology Drugs Market Analysis 2013–2021 and Forecast 2022–2028, By Distribution Channel

     20.1.Introduction/Key Finding

     20.2. Historical Market Size (US$ Mn) Trend Analysis By Distribution Channel, 2013-2021

            20.2.1. Hospital Pharmacy

            20.2.2. Retail Pharmacy

            20.2.3. Online Pharmacy

            20.2.4. Managed Care Institutions

     20.3.Market Size (US$ Mn) Forecast By Distribution Channel, 2022-2028

     20.4.Market Attractiveness Analysis By Distribution Channel

21. Global Generic Oncology Drugs Market Analysis 2013–2021 and Forecast 2022–2028

     21.1.Market Value Share Analysis By All Segment

     21.2.Y-o-Y Growth Analysis By All Segment

     21.3.Absolute $ Opportunity

22. Assumptions and Acronyms Used

23. Research Methodology

Customize this Report

Let us know your requirement to get
100% FREE customization

List of Tables

Table 01: Generic Oncology Drugs Expected to be Launched by end of 2022

Table 02: North America Generic Oncology Drugs Market Size (US$ Mn) Analysis 2013–2021 and Forecast 2022–2028, By Country

Table 03: North America Generic Oncology Drugs Market Size (US$ Mn) Analysis 2013–2021 and Forecast 2022–2028, By Molecule Type

Table 04: North America Generic Oncology Drugs Market Size (US$ Mn) Analysis 2013–2021 and Forecast 2022–2028, By Route of Administration

Table 05: North America Generic Oncology Drugs Market Size (US$ Mn) Analysis 2013–2021 and Forecast 2022–2028, By Distribution Channel

Table 06: Latin America Generic Oncology Drugs Market Size (US$ Mn) Analysis 2013–2021 and Forecast 2022–2028, By Country

Table 07: Latin America Generic Oncology Drugs Market Size (US$ Mn) Analysis 2013–2021 and Forecast 2022–2028, By Molecule Type

Table 08: Latin America Generic Oncology Drugs Market Size (US$ Mn) Analysis 2013–2021 and Forecast 2022–2028, By Route of Administration

Table 09: Latin America Generic Oncology Drugs Market Size (US$ Mn) Analysis 2013–2021 and Forecast 2022–2028, By Distribution Channel

Table 10: Western Europe Generic Oncology Drugs Market Size (US$ Mn) Analysis 2013–2021 and Forecast 2022–2028, By Country

Table 11: Western Europe Generic Oncology Drugs Market Size (US$ Mn) Analysis 2013–2021 and Forecast 2022–2028, By Molecule Type

Table 12: Western Europe Generic Oncology Drugs Market Size (US$ Mn) Analysis 2013–2021 and Forecast 2022–2028, By Route of Administration

Table 13: Western Europe Generic Oncology Drugs Market Size (US$ Mn) Analysis 2013–2021 and Forecast 2022–2028, By Distribution Channel

Table 14: Eastern Europe Generic Oncology Drugs Market Size (US$ Mn) Analysis 2013–2021 and Forecast 2022–2028, By Country

Table 15: Eastern Europe Generic Oncology Drugs Market Size (US$ Mn) Analysis 2013–2021 and Forecast 2022–2028, By Molecule Type

Table 16: Eastern Europe Generic Oncology Drugs Market Size (US$ Mn) Analysis 2013–2021 and Forecast 2022–2028, By Route of Administration

Table 17: Eastern Europe Generic Oncology Drugs Market Size (US$ Mn) Analysis 2013–2021 and Forecast 2022–2028, By Distribution Channel

Table 18: APECJ Generic Oncology Drugs Market Size (US$ Mn) Analysis 2013–2021 and Forecast 2022–2028, By Country

Table 19: APECJ Generic Oncology Drugs Market Size (US$ Mn) Analysis 2013–2021 and Forecast 2022–2028, By Molecule Type

Table 20: APECJ Generic Oncology Drugs Market Size (US$ Mn) Analysis 2013–2021 and Forecast 2022–2028, By Route of Administration

Table 21: APECJ Generic Oncology Drugs Market Size (US$ Mn) Analysis 2013–2021 and Forecast 2022–2028, By Distribution Channel

Table 22: China Generic Oncology Drugs Market Size (US$ Mn) Analysis 2013–2021 and Forecast 2022–2028, By Molecule Type

Table 23: China Generic Oncology Drugs Market Size (US$ Mn) Analysis 2013–2021 and Forecast 2022–2028, By Route of Administration

Table 24: China Generic Oncology Drugs Market Size (US$ Mn) Analysis 2013–2021 and Forecast 2022–2028, By Distribution Channel

Table 25: China Generic Oncology Drugs Market Size (US$ Mn) Analysis 2013–2021 and Forecast 2022–2028, By Molecule Type

Table 26: China Generic Oncology Drugs Market Size (US$ Mn) Analysis 2013–2021 and Forecast 2022–2028, By Route of Administration

Table 27: China Generic Oncology Drugs Market Size (US$ Mn) Analysis 2013–2021 and Forecast 2022–2028, By Distribution Channel

Table 28: MEA Generic Oncology Drugs Market Size (US$ Mn) Analysis 2013–2021 and Forecast 2022–2028, By Country

Table 29: MEA Generic Oncology Drugs Market Size (US$ Mn) Analysis 2013–2021 and Forecast 2022–2028, By Molecule Type

Table 30: MEA Generic Oncology Drugs Market Size (US$ Mn) Analysis 2013–2021 and Forecast 2022–2028, By Route of Administration

Table 31: MEA Generic Oncology Drugs Market Size (US$ Mn) Analysis 2013–2021 and Forecast 2022–2028, By Distribution Channel

Table 32: Global Generic Oncology Drugs Market Size (US$ Mn) Analysis 2013–2021 and Forecast 2022–2028, By Region

Table 33: Global Generic Oncology Drugs Market Size (US$ Mn) Analysis 2013–2021 and Forecast 2022–2028, By Molecule Type

Table 34: Global Generic Oncology Drugs Market Size (US$ Mn) Analysis 2013–2021 and Forecast 2022–2028, By Route of Administration

Table 35: Global Generic Oncology Drugs Market Size (US$ Mn) Analysis 2013–2021 and Forecast 2022–2028, By Distribution Channel

Sabyasachi Ghosh
Principal Consultant
LinkedIn
Talk to Analyst

Find your sweet spots for generating winning opportunities in this market.

Talk to Analyst

List of Charts

Figure 01: Generic Oncology Drugs Market Value Share By Region (2022)

Figure 02: Global Generic Oncology Drugs Market Share, By Region (2021)

Figure 03: Global Generic Oncology Drugs Market Share, By Molecule Type (2021)

Figure 04: Global Generic Oncology Drugs Market Share, By Route of Administration Type (2021)

Figure 05: Global Generic Oncology Drugs Market Share, By Distribution Channel (2021)

Figure 06: Distribution of Industry Sponsored Clinical Programs for Generic Oncology Drugs, by Phase

Figure 07: Number of Active Clinical Programs, by Major Indications

Figure 08: Geographical Distribution of Clinical Trials for Meningococcal Vaccines (2021)

Figure 09: North America Generic Oncology Drugs Market, Snapshot

Figure 10: North America Generic Oncology Drugs Market Value Share, by Country (2021)

Figure 11: North America Generic Oncology Drugs Market Value Share, by Molecule Type (2021)

Figure 12: North America Generic Oncology Drugs Market Value Share, by Distribution Channel (2021)

Figure 13: North America Generic Oncology Drugs Market Value Share, By Route of Administration (2021)

Figure 14: North America Generic Oncology Drugs Market Size (US$ Mn) Analysis, 2013–2021

Figure 15: North America Generic Oncology Drugs Market Size (US$ Mn) Forecast & Y-o-Y Growth (%), 2022–2028

Figure 16: North America Generic Oncology Drugs Market Attractiveness Analysis, By Country

Figure 17: North America Generic Oncology Drugs Market Attractiveness Analysis, By Molecule Type

Figure 18: North America Generic Oncology Drugs Market Attractiveness Analysis, By Distribution Channel

Figure 19: North America Generic Oncology Drugs Market Attractiveness Analysis, By Route of Administration

Figure 20: Latin America Generic Oncology Drugs Market, Snapshot

Figure 21: Latin America Generic Oncology Drugs Market Value Share, by Country (2021)

Figure 22: Latin America Generic Oncology Drugs Market Value Share, by Molecule Type (2021)

Figure 23: Latin America Generic Oncology Drugs Market Value Share, by Distribution Channel (2021)

Figure 24: Latin America Generic Oncology Drugs Market Value Share, By Route of Administration (2021)

Figure 25: Latin America Generic Oncology Drugs Market Size (US$ Mn) Analysis, 2013–2021

Figure 26: Latin America Generic Oncology Drugs Market Size (US$ Mn) Forecast & Y-o-Y Growth (%), 2022–2028

Figure 27: Latin America Generic Oncology Drugs Market Attractiveness Analysis, By Country

Figure 28: Latin America Generic Oncology Drugs Market Attractiveness Analysis, By Molecule Type

Figure 29: Latin America Generic Oncology Drugs Market Attractiveness Analysis, By Distribution Channel

Figure 30: Latin America Generic Oncology Drugs Market Attractiveness Analysis, By Route of Administration

Figure 31: Western Europe Generic Oncology Drugs Market, Snapshot

Figure 32: Western Europe Generic Oncology Drugs Market Value Share, by Country (2021)

Figure 33: Western Europe Generic Oncology Drugs Market Value Share, by Molecule Type (2021)

Figure 34: Western Europe Generic Oncology Drugs Market Value Share, by Distribution Channel (2021)

Figure 35: Western Europe Generic Oncology Drugs Market Value Share, By Route of Administration (2021)

Figure 36: Western Europe Generic Oncology Drugs Market Size (US$ Mn) Analysis, 2013–2021

Figure 37: Western Europe Generic Oncology Drugs Market Size (US$ Mn) Forecast & Y-o-Y Growth (%), 2022–2028

Figure 38: Western Europe Generic Oncology Drugs Market Attractiveness Analysis, By Country

Figure 39: Western Europe Generic Oncology Drugs Market Attractiveness Analysis, By Molecule Type

Figure 40: Western Europe Generic Oncology Drugs Market Attractiveness Analysis, By Distribution Channel

Figure 41: Western Europe Generic Oncology Drugs Market Attractiveness Analysis, By Route of Administration

Figure 42: Eastern Europe Generic Oncology Drugs Market, Snapshot

Figure 43: Eastern Europe Generic Oncology Drugs Market Value Share, by Country (2021)

Figure 44: Eastern Europe Generic Oncology Drugs Market Value Share, by Molecule Type (2021)

Figure 45: Eastern Europe Generic Oncology Drugs Market Value Share, by Distribution Channel (2021)

Figure 46: Eastern Europe Generic Oncology Drugs Market Value Share, By Route of Administration (2021)

Figure 47: Eastern Europe Generic Oncology Drugs Market Size (US$ Mn) Analysis, 2013–2021

Figure 48: Eastern Europe Generic Oncology Drugs Market Size (US$ Mn) Forecast & Y-o-Y Growth (%), 2022–2028

Figure 49: Eastern Europe Generic Oncology Drugs Market Attractiveness Analysis, By Country

Figure 50: Eastern Europe Generic Oncology Drugs Market Attractiveness Analysis, By Molecule Type

Figure 51: Eastern Europe Generic Oncology Drugs Market Attractiveness Analysis, By Distribution Channel

Figure 52: Eastern Europe Generic Oncology Drugs Market Attractiveness Analysis, By Route of Administration

Figure 53: APECJ Generic Oncology Drugs Market, Snapshot

Figure 54: APECJ Generic Oncology Drugs Market Value Share, by Country (2021)

Figure 55: APECJ Generic Oncology Drugs Market Value Share, by Molecule Type (2021)

Figure 56: APECJ Generic Oncology Drugs Market Value Share, by Distribution Channel (2021)

Figure 57: APECJ Generic Oncology Drugs Market Value Share, By Route of Administration (2021)

Figure 58: APECJ Generic Oncology Drugs Market Size (US$ Mn) Analysis, 2013–2021

Figure 59: APECJ Generic Oncology Drugs Market Size (US$ Mn) Forecast & Y-o-Y Growth (%), 2022–2028

Figure 60: APECJ Generic Oncology Drugs Market Attractiveness Analysis, By Country

Figure 61: APECJ Generic Oncology Drugs Market Attractiveness Analysis, By Molecule Type

Figure 62: APECJ Generic Oncology Drugs Market Attractiveness Analysis, By Distribution Channel

Figure 63: APECJ Generic Oncology Drugs Market Attractiveness Analysis, By Route of Administration

Figure 64: China Generic Oncology Drugs Market, Snapshot

Figure 65: China Generic Oncology Drugs Market Value Share, by Molecule Type (2021)

Figure 66: China Generic Oncology Drugs Market Value Share, by Route of Administration (2021)

Figure 67: China Generic Oncology Drugs Market Value Share, By Distribution Channel (2021)

Figure 68: China Generic Oncology Drugs Market Size (US$ Mn) Analysis, 2013–2021

Figure 69: China Generic Oncology Drugs Market Size (US$ Mn) Forecast & Y-o-Y Growth (%), 2022–2028

Figure 70: China Generic Oncology Drugs Market Attractiveness Analysis, By Molecule Type

Figure 71: China Generic Oncology Drugs Market Attractiveness Analysis, By Route of Administration

Figure 72: China Generic Oncology Drugs Market Attractiveness Analysis, By Distribution Channel

Figure 73: Japan Generic Oncology Drugs Market, Snapshot

Figure 74: Japan Generic Oncology Drugs Market Value Share, By Molecule Type (2021)

Figure 75: Japan Generic Oncology Drugs Market Value Share, By Route of Administration (2021)

Figure 76: Japan Generic Oncology Drugs Market Value Share, By Distribution Channel (2021)

Figure 77: Japan Generic Oncology Drugs Market Size (US$ Mn) Analysis, 2013–2021

Figure 78: Japan Generic Oncology Drugs Market Size (US$ Mn) Forecast & Y-o-Y Growth (%), 2022–2028

Figure 79: China Generic Oncology Drugs Market Attractiveness Analysis, By Molecule Type

Figure 80: China Generic Oncology Drugs Market Attractiveness Analysis, By Route of Administration

Figure 81: China Generic Oncology Drugs Market Attractiveness Analysis, By Distribution Channel

Figure 82: Middle East & Africa Generic Oncology Drugs Market, Snapshot

Figure 83: MEA Generic Oncology Drugs Market Value Share, by Molecule Type (2021)

Figure 84: MEA Generic Oncology Drugs Market Value Share, by Country (2021)

Figure 85: MEA Generic Oncology Drugs Market Value Share, by Distribution Channel (2021)

Figure 86: MEA Generic Oncology Drugs Market Value Share, By Route of Administration (2021)

Figure 87: Middle East & Africa Generic Oncology Drugs Market Size (US$ Mn) Analysis, 2013–2021

Figure 88: Middle East & Africa Generic Oncology Drugs Market Size (US$ Mn) Forecast & Y-o-Y Growth (%), 2022–2028

Figure 89: MEA Generic Oncology Drugs Market Attractiveness Analysis, By Country

Figure 90: MEA Generic Oncology Drugs Market Attractiveness Analysis, By Molecule Type

Figure 91: MEA Generic Oncology Drugs Market Attractiveness Analysis, By Distribution Channel

Figure 92: MEA Generic Oncology Drugs Market Attractiveness Analysis, By Route of Administration

Figure 93: Global Generic Oncology Drugs Market Attractiveness Analysis, By Region

Figure 94: Global Generic Oncology Drugs Market Value Share Analysis, By Region, 2021 & 2028

Figure 95: Global Generic Oncology Drugs Market Attractiveness Analysis, By Molecule Type

Figure 96: Global Generic Oncology Drugs Market Value Share Analysis, By Molecule Type, 2021 & 2028

Figure 97: Global Generic Oncology Drugs Market Attractiveness Analysis, By Route of Administration

Figure 98: Global Generic Oncology Drugs Market Value Share Analysis, By Route of Administration, 2021 & 2028

Figure 99: Global Generic Oncology Drugs Market Attractiveness Analysis, By Distribution Channel

Figure 100: Global Generic Oncology Drugs Market Value Share Analysis, By Distribution Channel, 2021 & 2028

Figure 101: Global Generic Oncology Drugs Market Size (US$ Mn) Analysis, 2013–2021

Figure 102: Global Generic Oncology Drugs Market Size (US$ Mn) Forecast & Y-o-Y Growth (%), 2022–2028

Figure 103: Global Generic Oncology Drugs Market Absolute $ Opportunity, 2013–2028

Need specific information?

Request Customization

Explore Healthcare Insights

View Reports

Recommendations

Healthcare

Sterile Oncology Injectable Market

Published : May 2018

Healthcare

Paediatric Oncology Therapeutics Market

Published : January 2017

Healthcare

Musculoskeletal Oncology Therapeutics Market

Published : June 2016

Healthcare

Orthopedic Oncology Market

Published : May 2016

Google translate

Generic Oncology Drugs Market